Source: Virtual Congress 2021 – Novel insights into the diagnosis, mechanism and treatment of malignant pleural disease



Rating:

Share or cite this content

Citations should be made in the following way:
K. Ferguson (Glasgow, United Kingdom), N. Hyndman (Glasgow, United Kingdom), F. Roberts (Glasgow, United Kingdom), K. Blyth (Glasgow, United Kingdom). The frequency of BAP1 and MTAP loss in Benign Asbestos-associated Pleural Inflammation. 1522

Member's Comments

No comment yet.

Related content which might interest you: Role of fibulin-3 in the diagnosis of malignant mesothelioma Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma Year: 2014 Malignant pleural disease Source: Annual Congress 2012 - PG16 ERS/ACCP joint course on diagnostic and management strategies for pleural disorders Year: 2012 Expression of YKL-40 and MIP-1a proteins in exudates and transudates: Biomarkers for differential diagnosis of pleural effusions? Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 Association of biochemical determinants and fibrinous formation in malignant pleural effusion Source: International Congress 2016 – Malignant pleural disease: diagnosis and management Year: 2016 1,25-dihydroxyvitamin D in malignant and non-malignant pleural effusions Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013 Hemorrhagic malignant pleural effusion: Diagnosis, survival rate, and response to talc pleurodesis Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 Analysis of amylase rich pleural effusions Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases Year: 2013 Management of recurrent Malignant Pleural Effusion: what is the best method? Source: School Course 2014 - Thoracoscopy and Pleural Techniques Year: 2014 Management of recurrent Malignant Pleural Effusion: what is the best method? Source: ERS Course 2015 Year: 2015 Validity of Pleural Fluid Protein in differentiating Tuberculous from Malignant Pleural Effusion Source: International Congress 2019 – Pleural infection and complicated pneumonia Year: 2019 Malignant pleural mesothelioma: A retrospective analysis of 32 cases Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 Management of spontaneous pneumothorax in patients with or without Birt-Hogg-Dubé syndrome Source: International Congress 2014 – ILDs 1 Year: 2014 Alteration of p53 and FHIT genes in pleural effusion associated with malignancy Source: Eur Respir J 2002; 20: Suppl. 38, 2s Year: 2002 Effect of asbestos on gene expression of tight junctions components in malignant pleural mesothelioma Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 Variation in outcomes for M1a Stage Lung cancers- Outcome in Malignant Pleural Effusion significantly worse than patients with Contralateral Lung Nodules Source: Virtual Congress 2021 – Accurate diagnosis and prediction of malignant pleural disease Year: 2021 Predictive value of pro-inflammatory cytokine and pro-angiogenic factor in differentiating malignant from benign exudative effusion Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 Haematologic parameters and their prognostic impact in malignant pleural mesothelioma Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 Malignant pleural effusion and incidence of pleural thickening in thorax CT Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 High fluorescence cells in pleural fluid. Association with pleural malignancy Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013